Liraglutide pretreatment attenuates sepsis-induced acute lung injury
Brandon Baer, Nathan D. Putz, Kyle Riedmann, Samantha Gonski, Jason Lin, Lorraine B. Ware, Shinji Toki, R. Stokes Peebles, Katherine N. Cahill, Julie A. Bastarache
2023American Journal of Physiology-Lung Cellular and Molecular Physiology36 citationsDOIOpen Access PDF
Abstract
In this study, pretreatment with liraglutide, a commonly used diabetes medication and glucagon-like peptide-1 (GLP-1) receptor agonist, attenuated sepsis-induced acute lung injury in a two-hit mouse model (sepsis + hyperoxia). Septic mice who received the drug were less sick, lived longer, and displayed reduced lung inflammation, edema, and injury. These therapeutic effects were not dependent on weight loss. GLP-1 receptor activation may hold promise as a new treatment strategy for sepsis-induced acute respiratory distress syndrome.
Topics & Concepts
LiraglutideSepsisMedicineAgonistLungInflammationAcute respiratory distressHyperoxiaGlucagon-like peptide 1 receptorReceptorDiabetes mellitusPharmacologyType 2 diabetesAnesthesiaInternal medicineEndocrinologyHyperglycemia and glycemic control in critically ill and hospitalized patientsNeuropeptides and Animal PhysiologySepsis Diagnosis and Treatment